Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.56 Average PT from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received an average recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $17.56.

Several analysts have recently issued reports on the stock. Needham & Company LLC lifted their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Finally, Barclays lifted their target price on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd.

Insider Activity

In other news, COO Scott Lish sold 27,453 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares of the company’s stock, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the sale, the chief executive officer now directly owns 5,501,715 shares in the company, valued at $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 222,376 shares of company stock valued at $2,557,148. Company insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in shares of Alphatec by 207.7% in the 3rd quarter. SG Americas Securities LLC now owns 44,603 shares of the medical technology company’s stock valued at $248,000 after buying an additional 30,108 shares in the last quarter. Creative Planning boosted its holdings in shares of Alphatec by 83.9% in the 3rd quarter. Creative Planning now owns 48,611 shares of the medical technology company’s stock valued at $270,000 after buying an additional 22,171 shares in the last quarter. Net Worth Advisory Group acquired a new position in shares of Alphatec in the 3rd quarter valued at $76,000. Tempus Wealth Planning LLC acquired a new position in shares of Alphatec in the 3rd quarter valued at $107,000. Finally, Courier Capital LLC boosted its holdings in shares of Alphatec by 105.3% in the 3rd quarter. Courier Capital LLC now owns 39,000 shares of the medical technology company’s stock valued at $217,000 after buying an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Down 0.5 %

Shares of NASDAQ ATEC opened at $10.61 on Monday. The company’s 50-day simple moving average is $10.48 and its 200-day simple moving average is $8.26. Alphatec has a 52-week low of $4.88 and a 52-week high of $15.69. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.29 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.